Pravafenix® is a fixed-dose combination of 40mg of pravastatin and 160mg of fenofibrate. The rationale behind the use of Pravafenix® is based on the increased residual cardiovascular risk observed in high risk patients with hypertriglyceridemia and/or low HDL cholesterol levels despite treatment with statins in monotherapy. In this article, we review the available evidence on the clinical efficacy of Pravafenix®, which shows complementary benefits in the overall lipid profile of high risk patients with mixed dyslipidemia not controlled with 40-mg pravastatin or 20-mg simvastatin. © 2014 Sociedad Española de Arteriosclerosis Elsevier España, S.L.
|Journal||Clinica e Investigacion en Arteriosclerosis|
|Publication status||Published - 1 Jan 2014|
- Atherogenic dyslipidemia
- Clinical efficacy
- Non-HDL cholesterol
- Residual cardiovascular risk